In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Esoterix Inc.

Division of Laboratory Corp. of America Holdings
www.esoterix.com

Latest From Esoterix Inc.

Quest buys LabOne: It's all about Synergies

For the past several years, Quest has successfully embarked on a consolidation strategy designed to serve its goal of gaining a competitive advantage, in laboratory testing, with superior distribution strength and increased patient access in a high-volume, low-margin industry. Quest's acquisition of LabOne is consistent with those objectives.
Business Strategies

Quest Strengthens Its Hand

Quest Diagnostics' purchase of American Medical Laboratories for $500 million in cash (including assumption of $160 million in debt) is one of a string of acquisitions made by large national laboratories in recent years. While it is by no means Quest's biggest or most strategically critical deal, it gives the nation's largest clinical laboratory a presence in two markets in which it was weak or had no presence, and shores up its rapidly growing esoteric testing business. The deal also eliminates a competitor.

Impath's Informatics Play

Impath's unorthodox step into the cancer information business has made it attractive to Wall Street, but will its vast, specialized databases allow it to reap benefits from pharmacogenetics? The real value to Impath of its databases resides in their ability to promote work on targeted therapeutics, whose use in patients will depend on critical markers. But targeted therapeutics are a controversial concept that requires pharma companies to make basic changes in the way they operate. There's no guarantee Impath can get the pay-off it wants from its new initiatives.
Strategy Business Strategies

A Light Amidst the Diagnostics Devastation

In the financially besieged clinical laboratory industry, some investors see a bright spot: esoteric labs. Behrman Capital has established Esoterix Inc. to identify and acquire leading providers of esoteric laboratory services focused on specific fields like endocrinology or genetics.
Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Contract Research, Toxicology Testing-CRO
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Hematology, Coagulation
    • Molecular Diagnostics & Genetic Testing
  • Laboratory Testing Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Esoterix Endocrinology
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Laboratory Corp. of America Holdings
  • Senior Management
  • Frank Spina, EVP, CFO
  • Contact Info
  • Esoterix Inc.
    Phone: (800) 444-9111
    4509 Freidrich Lane, Bldg. 1, Ste. 100
    Austin, TX 78744
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register